GeneseeqPrime Gains FDA 510(k) Clearance for Tumor Profiling Kit
TORONTO, Sept. 2, 2025 – Geneseeq Technology Inc. announced that its GeneseeqPrime® NGS Tumor Profiling Assay has received 510(k)...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Medical Devices, Diagnostics, Radiation-Emitting Products
TORONTO, Sept. 2, 2025 – Geneseeq Technology Inc. announced that its GeneseeqPrime® NGS Tumor Profiling Assay has received 510(k)...
PHOENIX, August 28, 2025 — Five amniotic membrane allograft products have received official recognition from the FDA’s Tissue Reference...
MINNEAPOLIS, August 29, 2025 — Phraxis announced the successful completion of the first-ever commercial case using its EndoForce Anastomotic...
Imbed Biosciences has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE)...
Terumo Corporation is acquiring UK-based OrganOx Limited for approximately USD 1.5 billion, enhancing its entry into the organ transplantation...
ANKARA, Türkiye, August 18, 2025 — SmartAlpha’s AI-powered software, Nerveblox, designed to assist clinicians performing ultrasound-guided regional anesthesia (“nerve...
